An outbreak of COVID-19 (Coronavirus Disease in 2019) caused by the novel coronavirus, officially named SARS-CoV-2, has brought a huge impact on the lives of people both in China and abroad. In order to effectively address COVID-19 as a public health threat, we need an in-depth understanding of its infection and immune mechanism.

An outbreak of COVID-19 (Coronavirus Disease in 2019) caused by the novel coronavirus, officially named SARS-CoV-2, has brought a huge impact on the lives of people both in China and abroad. In order to effectively address COVID-19 as a public health threat, we need an in-depth understanding of its infection and immune mechanism.

An outbreak of COVID-19 (Coronavirus Disease in 2019) caused by the novel coronavirus, officially named SARS-CoV-2, has brought a huge impact on the lives of people both in China and abroad. In order to effectively address COVID-19 as a public health threat, we need an in-depth understanding of its infection and immune mechanism.

An outbreak of COVID-19 (Coronavirus Disease in 2019) caused by the novel coronavirus, officially named SARS-CoV-2, has brought a huge impact on the lives of people both in China and abroad. In order to effectively address COVID-19 as a public health threat, we need an in-depth understanding of its infection and immune mechanism.

Cyagen’s experts have investigated the known characteristics of SARS-CoV-2, similarities to related coronaviruses, potential antiviral targets, and lessons learned from the outbreak from a research perspective — which we have assembled to assist in such research efforts. In our newly published White Paper, we discuss various research opportunities to combat the COVID-19 outbreak, including: targeted immunotherapy, SC-1 peptide, SARS-CoV-2 S-RBD neutralizing monoclonal antibodies (mAbs), and vaccine development based on human receptor ACE2.

Cyagen’s experts have investigated the known characteristics of SARS-CoV-2, similarities to related coronaviruses, potential antiviral targets, and lessons learned from the outbreak from a research perspective — which we have assembled to assist in such research efforts. In our newly published White Paper, we discuss various research opportunities to combat the COVID-19 outbreak, including: targeted immunotherapy, SC-1 peptide, SARS-CoV-2 S-RBD neutralizing monoclonal antibodies (mAbs), and vaccine development based on human receptor ACE2.

White Paper: Infectivity and Immune Mechanisms of Coronaviruses & SARS-CoV-2
This free resource covers:
● The brief introduction to Coronavirus
● Characteristics & Correlations of SARS-CoV, MERS-CoV, and SARS-CoV-2
● Methods to defend against COVID-19
● What we have learned from the 2019 outbreak

Visit Our Page for Your Free PDF Download

Accurate animal models are necessary for verifying the pathogenesis and immune mechanisms of the illness to accelerate research across vaccine development, new antiviral drug development, gene therapy, and more. As our way of contributing to the international epidemic prevention effort for SARS-CoV-2, Cyagen is opening services on accurate models for coronavirus receptor targets, such as ACE2 and DPP4, effective immediately.

1. For humanized models, knockout models, Rosa26 knockin mouse models of ACE2 and DPP4 on C57BL/6 mouse strains, the exclusive sales prices are as below:

ACE2/DPP4 Service Name Deliverable Promotion Price (USD/Strain)
Knockout Mice ≧3 Mice $3,599
Humanized Mice ≧3 Mice $8,400
Knockin Mice (Rosa26) ≧3 Mice $9,600

2. In addition to ACE2 and DPP4, if you would like to order any other models related to the research of SARS-CoV-2, corroborating materials on its feasibility should be provided. Once approved by our experts, you will be offered the promotional price as well.

3. Cyagen can also offer mouse models in BALB/c background, please contact us for further information.

Feel free to reply directly for more information about how we may help support your research goals.

Добавить комментарий

Ваш e-mail не будет опубликован. Обязательные поля помечены *